Drugs Made In America Acquisition DMII
NASDAQ DMII
$10.14 +0.00 (+0.00%)
As of: Aug 21, 2026 · 2:38 PM EDT

Drugs Made In America Acquisition (DMII) Accumulated Expenses (2025)

Drugs Made In America Acquisition (DMII) posted quarterly Accumulated Expenses of $88343.0 for Q4 2025, up 1411.95% quarter-over-quarter from $5843.0 in Q3 2025.

Drugs Made In America Acquisition (DMII) Accumulated Expenses (2025) Analysis & Trends

Drugs Made In America Acquisition (DMII) has reported Accumulated Expenses for 1 consecutive years, with $88343.0 the latest figure, recorded in Q4 2025.

  • In Q4 2025, Accumulated Expenses changed N/A year-over-year to $88343.0; the TTM figure through Dec 2025 stood at $88343.0 (changed N/A YoY), while the FY2025 annual figure was $88343.0, changed N/A from the prior year.
  • Accumulated Expenses rose to $88343.0 in Q4 2025 per DMII's latest filing, from $5843.0 in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $88343.0 in Q4 2025 and bottomed at $5843.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oxley Bridge Acquisition 585.76 Mn 585.76 Mn -
2 Launch Two Acquisition 557.86 Mn 557.86 Mn -
3 Drugs Made In America Acquisition 507.00 Mn 507.00 Mn -
4 Cantor Equity Partners IV 468.00 Mn 468.00 Mn -
5 GP-Act III Acquisition 401.06 Mn 401.06 Mn -
6 Aldel Financial 397.49 Mn 397.49 Mn -
7 Republic Digital Acquisition 389.25 Mn 388.51 Mn -
8 Gores Holdings X 385.06 Mn 384.87 Mn -
9 Agriculture & Natural Solutions Acquisition 377.29 Mn 377.04 Mn -
10 CSLM Digital Asset Acquisition Corp III 322.52 Mn 314.90 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2025 88,343.00
Sep 30, 2025 5,843.00